The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 124 participants.
Also called NCT06606821
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 124 participants
- Sponsor
- Tina Vilsbøll
- Registry
-
NCT06606821 -
2023-505270-15-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Recruiting
Technical summary
Registry record NCT06606821. Randomized; triple masking; primary purpose treatment. Start 2024-10-01 (actual); primary completion 2027-03-20 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
- Acronym
- IDEAL-COR
- Condition
- Coronary Artery Disease
- Condition
- Coronary Microvascular Dysfunction
- Condition
- Overweight or Obesity
- Condition
- Stable Angina Pectoris
- Condition
- Chronic Coronary Artery Disease
- Condition
- Atherosclerosis Cardiovascular Disease
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Tina Vilsbøll
Record details
- Record id
cardio:ct-nct06606821- Content hash
5844a4e3856090d4c14c57052ef5c04de480abe5a6f14953f9960070d44bd026